115 related articles for article (PubMed ID: 21196049)
1. A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III.
Leong WS; Thomas KA; Chan CH; Stevenson GT
Mol Immunol; 2011 Feb; 48(5):760-8. PubMed ID: 21196049
[TBL] [Abstract][Full Text] [Related]
2. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of human Fc gamma in closed-hinge or open-hinge configuration to Fab'gamma and analogous ligands.
Stevenson GT; Anderson VA; Kan KS; Worth AT
J Immunol; 1997 Mar; 158(5):2242-50. PubMed ID: 9036971
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
5. Bispecific F(ab'gamma)3 antibody derivatives for redirecting unprimed cytotoxic T cells.
Tutt A; Greenman J; Stevenson GT; Glennie MJ
Eur J Immunol; 1991 Jun; 21(6):1351-8. PubMed ID: 1828423
[TBL] [Abstract][Full Text] [Related]
6. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis.
Wijngaarden S; van de Winkel JG; Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Rheum; 2004 Dec; 50(12):3878-87. PubMed ID: 15593228
[TBL] [Abstract][Full Text] [Related]
7. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
8. FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation.
Kim HY; Kim S; Chung DH
J Clin Invest; 2006 Sep; 116(9):2484-92. PubMed ID: 16917543
[TBL] [Abstract][Full Text] [Related]
9. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.
Johnson S; Burke S; Huang L; Gorlatov S; Li H; Wang W; Zhang W; Tuaillon N; Rainey J; Barat B; Yang Y; Jin L; Ciccarone V; Moore PA; Koenig S; Bonvini E
J Mol Biol; 2010 Jun; 399(3):436-49. PubMed ID: 20382161
[TBL] [Abstract][Full Text] [Related]
10. Fcγ receptors inhibit mouse and human basophil activation.
Cassard L; Jönsson F; Arnaud S; Daëron M
J Immunol; 2012 Sep; 189(6):2995-3006. PubMed ID: 22908332
[TBL] [Abstract][Full Text] [Related]
11. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
[TBL] [Abstract][Full Text] [Related]
12. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
[TBL] [Abstract][Full Text] [Related]
13. Thioether-bonded constructs of Fab'gamma and Fc gamma modules utilizing differential reduction of interchain disulfide bonds.
Kan KS; Anderson VA; Leong WS; Smith AM; Worth AT; Stevenson GT
J Immunol; 2001 Jan; 166(2):1320-6. PubMed ID: 11145716
[TBL] [Abstract][Full Text] [Related]
14. Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis.
Hellwig SM; van Oirschot HF; Hazenbos WL; van Spriel AB; Mooi FR; van De Winkel JG
J Infect Dis; 2001 Mar; 183(6):871-9. PubMed ID: 11237803
[TBL] [Abstract][Full Text] [Related]
15. Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis.
Syam S; Mero P; Pham T; McIntosh CA; Bruhns P; Booth JW
J Immunol; 2010 Mar; 184(6):2966-73. PubMed ID: 20154205
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
17. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.
White DM; Jensen MA; Shi X; Qu Zx ; Arnason BG
Protein Expr Purif; 2001 Apr; 21(3):446-55. PubMed ID: 11281720
[TBL] [Abstract][Full Text] [Related]
18. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
[TBL] [Abstract][Full Text] [Related]
19. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis.
Schiller C; Janssen-Graalfs I; Baumann U; Schwerter-Strumpf K; Izui S; Takai T; Schmidt RE; Gessner JE
Eur J Immunol; 2000 Feb; 30(2):481-90. PubMed ID: 10671203
[TBL] [Abstract][Full Text] [Related]
20. Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target.
Abès R; Dutertre CA; Agnelli L; Teillaud JL
Expert Rev Clin Immunol; 2009 Nov; 5(6):735-47. PubMed ID: 20477693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
